APLS - Apellis Pharmaceuticals

-

$undefined

N/A

(N/A)

Apellis Pharmaceuticals NasdaqGS:APLS Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Location: 100 Fifth Avenue, Waltham, MA, 02451, United States | Website: https://apellis.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.30B

Cash

362.3M

Avg Qtr Burn

-2.073M

Short % of Float

34.06%

Insider Ownership

13.73%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SYFOVRE™ (Intravitreal pegcetacoplan) Details
Geographic atrophy, Age-related macular degeneration

Approved

Quarterly sales

Empaveli (systemic pegcetacoplan) (APL-2) Details
Paroxysmal nocturnal hemoglobinuria

Approved

Quarterly sales

Systemic pegcetacoplan (APL-2) Details
Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy

PDUFA

Approval decision

Systemic pegcetacoplan (APL-2) Details
Hematopoietic stem cell transplantation thrombotic microangiopathies

Phase 2

Data readout

Systemic pegcetacoplan (APL-2) Details
Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy

Phase 2

Update

APL-3007 + SYFOVRE Details
Autoimmune disease, Inflammatory disease

Phase 2

Initiation

Intravenous APL-9 Details
ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies)

Failed

Discontinued

Failed

Discontinued

Systemic pegcetacoplan (APL-2) Details
Amyotrophic lateral sclerosis

Failed

Discontinued